Dr. Scott M. Rocklage, PhD, is the Managing Partner of 5AM Ventures. He brings to the table more than 30 years of healthcare experience with a focus on strategic leadership. Past experience includes management roles with Cubist Pharmaceuticals, Nycomed Salutar and Catalytica. Rocklage has also worked the research and design (R&D) side of pharmaceuticals, as well.
His educational background includes earning a Bachelor of Science (B.S.) degree in Chemistry from the University of California at Berkeley and a Doctor of Philosophy (Ph.D.) degree in Chemistry from the Massachusetts Institute of Technology (MIT). Learn more about Jim Larkin: https://scottrocklage.wordpress.com/
While at MIT, Dr. Rocklage conducted research in the laboratory of Richard R. Schrock, who won a Nobel Prize in Chemistry in 2005.
Dr. Rocklage is credited with more than 30 U.S. Patents. Rocklage also serves on the Boards of Achaogen, Semprus and Relypsa, along with Variation, Pulmatrix and WaveRx. Rocklage also serves on the Board of the Whitehead Institute.
5AM Ventures is committed to building next generation life science companies. Rocklage and his team create value in the early stages of such entities with hands on approach including leading edge investments. The team at 5AM supports companies that are working to solve healthcare needs with cutting edge science and medicine.
The companies supported by 5AM are those that take the off-beat approach to finding unique approaches to prevent, diagnose and treat a variety of medical conditions.
5AM Ventures was founded in 2002 and currently has more than $1 billion in management. The company maintains offices in San Francisco, California and Boston, Massachusetts, where Dr. Rocklage is located.
Part of the 5AM team is made up of 18 investment professionals with significant operating experience. The 5AM team contributes to start-ups by taking on board member roles, as well as short-term management roles.
Dr. Rocklage works with entrepreneurs to help them take their ideas and shape them into medicines that can be used to treat a variety of medical conditions. He sees a trend in the ability to identify and target specific genotypes and mutations that treat cancer in unique and more effective ways.